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Various techniques have been employed to detect BCR-ABL kinase domain mutations in
patients with chronic myeloid leukemia who are resistant to imatinib. This has led to differ-
ent reported frequencies of mutations and the finding of a heterogeneous pattern of individ-
ual mutations. 
Design and Methods
We compared direct sequencing alone and in combination with denaturing high-perform-
ance liquid chromatography and two high-sensitivity allele-specific oligonucleotide poly-
merase chain reaction approaches for analysis of BCR-ABL mutations in 200 blinded cDNA
samples prior to and during second-line dasatinib or nilotinib therapy in patients with chron-
ic myeloid leukemia in whom imatinib treatment had failed.
Results
One hundred and fourteen mutations were detected by both direct sequencing alone or in
combination with high performance liquid chromatography and 13 mutations were addi-
tionally detected by the combined technique. Eighty of 83 mutations (96%) within a select-
ed panel of 11 key mutations were confirmed by both allele-specific oligonucleotide poly-
merase chain reaction techniques and 62 mutations were identified in addition to those
detected by combined liquid chromatography and direct sequencing, indicating the presence
and a high prevalence of low-level mutations in this cohort of patients. Furthermore, 125
mutations were detected by only one allele-specific oligonucleotide polymerase chain reac-
tion technique. Pre-existing mutations were traceable 4.5 months longer and emerging
clones were detectable 3.0 months earlier by allele-specific oligonucleotide polymerase chain
reaction than by direct sequencing together with liquid chromatography.
Conclusions
Our results suggest that denaturing high performance liquid chromatography combined
with direct sequencing is a reliable screening technique for the detection of BCR-ABL kinase
domain mutations. Allele-specific oligonucleotide polymerase chain reaction further increas-
es the number of detected mutations and indicates a high prevalence of mutations at a low
level. The clinical impact of such low-level mutations remains uncertain and requires further
investigation. Allele-specific oligonucleotide polymerase chain reaction allows detection of
defined mutations at a lower level than does denaturing high performance liquid chroma-
tography combined with direct sequencing and may, therefore, provide clinical benefit by
permitting early reconsideration of therapeutic strategies.
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Introduction
The advent of imatinib mesylate has revolutionized
the treatment of patients with chronic myeloid leukemia
(CML).1 After the 7-year follow-up of the IRIS study, the
estimated overall survival of patients who received ima-
tinib as initial therapy was 86% and freedom from pro-
gression to accelerated phase or blast crisis was 93%.2
However, a minority of patients in chronic phase and a
substantial proportion of patients in advanced phases of
CML are either initially refractory to imatinib treatment
or lose sensitivity to imatinib over time and thereby
experience relapse.3 The most frequently identified
mechanism of acquired imatinib resistance is the emer-
gence of point mutations within the BCR-ABL kinase
domain impairing imatinib binding either by interfer-
ence with the imatinib binding site or by stabilizing a
BCR-ABL conformation with reduced binding affinity
for imatinib.4 To date, more than 70 different BCR-ABL
kinase domain mutations, encoding for more than 50
different amino acid substitutions, have been described
in imatinib-resistant CML patients.5
Various techniques have been employed to detect
BCR-ABL kinase domain mutations, resulting in differ-
ent reported frequencies of mutations and the finding of
a heterogeneous pattern of individual mutations. There
is currently no consensus concerning the technique that
should be used for routine monitoring of CML patients
and there are still difficulties in clinical interpretation of
specific mutations. One particularly reliable and sensi-
tive approach is the selection and expansion of specific
clones followed by DNA sequencing.6,7 However, this
procedure is cumbersome and not suitable for routine
clinical analysis. As an alternative, sequencing of nested
polymerase chain reaction (PCR)-amplified BCR-ABL
products has been widely used to search for known and
unknown BCR-ABL kinase domain mutations.8,9 A
potential drawback of direct sequencing (DS) is its detec-
tion sensitivity of only 10-20%. In comparison, sensitiv-
ities of 1-5% can be obtained using denaturing high-per-
formance liquid chromatography (D-HPLC),10-13 double-
gradient denaturing electrophoresis,14 pyrosequencing,15
high-resolution melting,16 or array-based assays.17,18 More
sensitive methods include peptide nucleic acid-based
PCR clamping19 and allele-specific oligonucleotide (ASO)
PCR.20-23 However, these techniques are specific for
known mutations and cannot be applied for screening of
unknown mutations. To date, these methods have been
used for scientific purposes – such as quantification of
low-level drug resistance – rather than clinically relevant
monitoring of drug-resistant clones. A comparative
assessment of technical features characterizing individ-
ual detection techniques has not been performed to date.
In this study we sought to compare different tech-
niques for the detection of BCR-ABL kinase domain
mutations in CML patients after imatinib failure. Serial
blinded samples from patients on second-generation
tyrosine kinase inhibitor (TKI) therapy were simultane-
ously analyzed using two screening methods (DS and D-
HPLC in combination with DS) and two high-sensitivi-
ty ASO PCR techniques: an amplification refractory
mutation system (ARMS) PCR and ligation-PCR (L-
PCR). In particular, we sought to evaluate (i) the reliabil-
ity of D-HPLC/DS results compared to DS and (ii)
whether ASO PCR-based genotyping approaches –
despite their obvious drawback of detecting known
mutations only – confer a clinically advantageous level
of sensitivity of mutation detection which eventually
could justify implementation of these techniques in clin-
ical monitoring of CML patients.
Design and Methods
Patients’ samples
In total, 200 blood samples from 40 BCR-ABL-positive
CML patients with treatment failure or suboptimal
response to imatinib according to the European
LeukemiaNet recommendations24 were investigated. All
patients gave written informed consent, had previously
received between 400 and 800 mg imatinib/day and
were included in the clinical trials NCT00109707,
NCT00384228, CA180013, CA180005 and CA180006
(www.clinicaltrials.gov). These trials were conducted in
accordance with the Helsinki Declaration of 1975, as
revised in 2000, and approved by national and/or interna-
tional ethics committees. The patients’ characteristics are
given in Table 1. Mutation analysis was performed prior
to start of second-line TKI therapy with dasatinib 140
mg/day (n=20) or nilotinib 800 mg/day (n=20) and after
3, 6, 9, and 12 months on therapy. Patients were random-
ly selected and samples were blinded in the Mannheim
(Germany) laboratory. Two hundred cDNA aliquots
were shipped to each of the other two participating lab-
oratories in Leipzig (Germany), and Tromsø (Norway).
RNA extraction and cDNA synthesis
Total RNA was extracted after hypotonic red cell lysis
from at least 20 mL of peripheral blood using the
RNeasy® Mini Kit (Qiagen, Hilden, Germany) or TRIzol®
reagent (Invitrogen, Karlsruhe, Germany) according to
the manufacturers’ instructions. Complementary DNA
synthesis was performed using random hexamer
primers and MMLV reverse transcriptase (Invitrogen) as
described elsewhere.25




Age Median [years] 64
Range 39-78
Phase of disease Chronic phase 31
Accelerated phase 7
Myeloid blast crisis 2
Mutation status Mutation 29
No mutation 11
Second-line TKI therapy Dasatinib 20
Nilotinib 20
TKI: tyrosine kinase inhibitor.
Quantitative reverse-transcriptase polymerase 
chain reaction
BCR-ABL, total ABL and β-glucuronidase (GUS) tran-
scripts were amplified in Mannheim using the
LightCyclerTM technology (Roche Diagnostics, Mann-
heim, Germany) and detected via specific hybridization
probes as described previously.26,27 The control genes
were selected based on recommendations of the Europe
Against Cancer (EAC) protocol.28 Two microliters of
cDNA were used as the template for the quantitative
reverse transcriptase-PCR reactions.
Direct sequencing
DS was performed in Tromsø as described previous-
ly.9 Hemi-nested PCR products of 675 bp encoding
amino acids 207-414 were amplified and sequenced in
both directions using an ABI PRISM® 3130 Genetic
Analyzer and the BigDye Terminator kit version 3.1
(Applied Biosystems, Foster City, CA, USA). Sequences
were compared with the wild-type ABL sequence
(GenBank accession no. U07563). In our hands this
approach allows the detection of mutations if the
mutated transcripts represent at least 20% of the entire
BCR-ABL transcriptome using mutant BaF/3 cell line
dilution series.
Denaturing high-performance liquid chromatography
in combination with direct sequencing
D-HPLC was performed in Mannheim on a Trans-
genomic WaveTM System Model 3500 HT (Trans-
genomic, Omaha, NE, USA) according to previous
descriptions.13 This technique is based on heteroduplex
formation by PCR products amplified from wild-type
and mutant alleles and allows high throughput screen-
ing applications. Briefly, three overlapping fragments
covering the entire BCR-ABL kinase domain (amino
acids 207 through 517) were generated by nested PCR
and analyzed for the presence of sequence variations by
D-HPLC. PCR products with an abnormal D-HPLC pro-
file were sequenced in both directions to characterize
the precise nucleotide substitution(s) and compared to
the ABL wild-type sequence (GenBank accession no.
U07563). Growth factor-independent Ba/F3 cell popula-
tions expressing full-length non-mutated BCR-ABL or
full-length BCR-ABL with the clinically most common
BCR-ABL kinase domain mutations Y253F, E255K,
T315I or M351T were used to optimize the D-HPLC
assay and to estimate its sensitivity. Using serial dilu-
tions the detection limit for T315I and M351T muta-
tions was estimated as 0.1%, whereas the limits for the
Y253F and E255K mutations were 0.5% and 1%,
respectively. Selected mutant and non-mutant Ba/F3 cell
lines were used as internal controls for each D-HPLC
run. ABL single nucleotide polymorphisms were identi-
fied as described previously and excluded from this
study.29
Amplification refractory mutation system polymerase
chain reaction
ARMS PCR was performed in Tromsø according to
previous descriptions.21 Complementary DNA corre-
sponding to 80 ng RNA was subjected to a single step of
PCR amplification (95°C 10 for min, 50 cycles of 95°C
for 30 seconds, 60°C for 30 seconds, 72°C for 1 min)
using assays which were optimized for selective ampli-
fication of mutations known to confer TKI resistance
[total volume 25 µL, 2x master mix (Eurogentec,
Brussels), 1 µM Taqman probe, 2 µM primers, Mx3000P
real time platform (Stratagene, La Jolla, CA, USA)].
Briefly, primers were chosen to complement the mutat-
ed allele at the 3’-end. For the purpose of increased
affinity the primers contained additional mismatches
allowing a preferential amplification of the mutated
template over an almost 4-log range. Samples giving rise
to amplification curves crossing a threshold significant-
ly earlier compared to curves derived from non-mutant
Ba/F3 cells were classified as positive. The resulting Ct
values were subsequently translated into copy numbers
after comparison to standard curves derived from
amplification of a 10-fold diluted plasmid containing the
respective mutation (pCR 2.1 vector, linearized with
HindIII). For normalization, copy numbers were finally
related to total BCR-ABL and expressed as BCR-
ABLmutant/BCR-ABLtotal. This single step approach has pre-
viously been shown to detect mutated transcripts if
they contribute at least 0.1% of the total BCR-ABL and
ABL transcript count.21 
Ligation polymerase chain reaction
L-PCR was performed in Leipzig as described previ-
ously.23 In addition to the already described hybridiza-
tion, ligation, and quantification procedures to detect
BCR-ABLT315I and BCR-ABLE255K, additional hybridization
probes were used for the remaining mutations (Online
Supplementary Table S1). In serial 4-fold dilutions of
Ba/F3 cells expressing BCR-ABLT315I or BCR-ABLE255K
mutants in Ba/F3 cells expressing non-mutated BCR-
ABL, mutation-specific L-PCR assays achieved detec-
tion sensitivities of 0.1% to 0.05% BCR-ABLmutant/BCR-
ABLtotal. Similar sensitivities were achieved for the other
mutations tested with the exception of BCR-ABLM351T,
which was detectable only down to 5%. Ba/F3 cells
expressing non-mutated BCR-ABL were used as nega-
tive controls in order to reveal any cross-reactivity with
the mutation-specific oligonucleotides. Samples were
scored positive only if the Ct values of the sample did
not exceed those of 0.05% BCR-ABLmutant/BCR-ABLtotal
and those of the negative control in two independent
reactions. The dynamic range of the L-PCR approach,
which is particularly important for the successful moni-
toring of a mutant clone, typically covers 100% to
<0.1% or 0.05% mutant (3–3.5 log). Ba/F3 cell lines con-
taining the respective BCR-ABLmutant or patients’ samples
with a known ratio of BCR-ABLmutant/BCR-ABLtotal were
used as positive controls in all assays. The comparative
Ct method was used to calculate the relative percentage
of mutated cells in the positive samples directly accord-
ing to the equation: % mutant allele = 2 -(ct BCR-ABLmutant – ct BCR-
ABLtotal) x 100. The robustness of the PCR conditions con-
tributes to a very low inter-assay variation in the calcu-
lated reproducibility of mutants of around 20% (0.2 log)
over the entire detection range (data not shown).
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haematologica | 2009; 94(9) | 1229 |
T. Ernst et al. 
| 1230 | haematologica | 2009; 94(9)
Statistical analysis
Since DS and D-HPLC/DS led to dichotomous results
(mutation detection yes or no), the scaling of both param-
eters was always categorical. In general, BCR-ABL/ABL
and BCR-ABL/GUS ratios as well as the various muta-
tion levels measured by ARMS or L-PCR are given as
continuous data. If frequencies of mutation detection
were compared between the methods, results of ARMS-
and L-PCR were dichotomized (mutation detection yes
or no) as well. To assess the relation between two cate-
gorical variables, Fisher’s exact test was applied. Groups
with continuous data were compared by the Mann-
Whitney U test. The association between two continu-
ous parameters was described by the Spearman’s rank
correlation coefficient. Due to the explorative nature of
the analyses, the level of statistical significance was 0.05
for all tests. Only two-sided p values were recorded. All
calculations were performed using SAS/STAT software,
Version 9.1.3 for PC.
Results
BCR-ABL/ABL and BCR-ABL/GUS ratios
BCR-ABL fusion mRNA was quantified and related to
the expression of two reference genes prior to and at 3-
monthly intervals during second-line dasatinib (n=20) or
nilotinib (n=20) therapy. Median BCR-ABL/total ABL
and BCR-ABL/GUS ratios were 90% (range, 5.5-260%)
and 21% (range, 0.56-128%) in patients prior to dasa-
tinib therapy. After 12 months of dasatinib therapy,
BCR-ABL/total ABL and BCR-ABL/GUS ratios were
reduced to 4.5% (range, 0-71%) and 2.1% (range, 0-
34%), respectively. Median BCR-ABL/total ABL and
BCR-ABL/GUS ratios were 56% (range, 11-100%) and
17% (range, 4.8-109%) in patients prior to nilotinib ther-
apy. After 12 months of nilotinib therapy, BCR-
ABL/total ABL and BCR-ABL/GUS ratios were reduced
to 8.2% (range, 0-81%) and 2.9% (range, 0-65%),
respectively.
Analyzed samples and number of detected mutations
In total, 174 of 200 samples (87%) were comparable
between the different mutation detection approaches.
The remaining 26 samples had a BCR-ABL/total ABL
ratio <0.1% on second line TKI therapy and the amplifi-
cation of BCR-ABL failed in at least one laboratory.
Table 2 gives an overview of all mutations detected by
the four different methods in regard to the underlying
second-line TKI therapy. In total, 667 mutations were
identified (DS, n=114; D-HPLC/DS, n=142; ARMS,
n=191; L-PCR, n=220).
Comparison of direct sequencing alone and
in combination with denaturing high-performance 
liquid chromatography
To analyze the reliability of D-HPLC as a screening
method for routine use we compared DS of all samples
to the results obtained by D-HPLC in combination with
sequencing of suspect D-HPLC products (D-HPLC/DS).
Analyzed sequences of DS and D-HPLC/DS overlapped
at ABL type 1a amino acids 207 to 414. One hundred
and fourteen mutations affecting 16 different amino
acids were detected by both techniques in 100 of 174
samples. DS did not detect any mutations which were
not identified by D-HPLC/DS. In contrast, D-HPLC/DS
detected 13 additional mutations which were not found
by DS, resulting in a total of 127 mutations affecting 19
amino acids in 104 of 174 samples. Of these 13 muta-
tions, nine (69%) were minor clones of compound
mutations with a low proportion of mutant alleles.
Differences between DS and D-HPLC/DS were not sta-
tistically different (Fisher’s exact test).
Comparison of denaturing high-performance liquid
chromatography in combination with direct 
sequencing and allele-specific oligonucleotide 
polymerase chain reaction
ASO PCR was performed for a panel of 11 clinically
relevant mutations (G250E, Q252H, Y253H/F, E255K/V,
V299L, T315I, F317L, M351T, F359V) according to the
respective ARMS and L-PCR techniques. The number of
mutations detected by the different methods are shown
for individual mutations in Figure 1 and summarized in
Table 3. Eighty of 83 mutations (96%) detected by D-
HPLC/DS within the ASO PCR panel were confirmed
by both PCR techniques [G250E (n=14), Q252H (n=1),
Y253F (n=5), Y253H (n=3), E255K (n=7), E255V (n=9),
T315I (n=15), F317L (n=12), M351T (n=4), F359V
(n=10)] and referred to as high-level mutations with a
median proportion of mutant alleles of 49% (range,
0.79%-100%) BCR-ABLmutant/BCR-ABLtotal (Figure 2A).
One F317L mutation was missed by both ASO PCR
methods and one F317L by ARMS and one G250E by L-
PCR. D-HPLC/DS detected 59 additional mutations out-
side the mutation panel of the ASO PCR assays. A total
of 187 mutations [G250E (n=10), Q252H (n=3), Y253H
(n=23), E255K (n=23), E255V (n=3), V299L (n=9), T315I
(n=58), F317L (n=26), M351T (n=15), F359V (n=17)] in
120 of 174 samples were additionally detected by both
or only one of the specific ASO PCR techniques and
were not found by D-HPLC/DS. Significant differences
(Fisher’s exact test) in the number of detected mutations
between D-HPLC/DS and both ASO PCR methods were
identified for the following mutations: Y253H
(p=0.0006), E255K (p=0.0008), T315I (p=0.0077 [D-
HPLC/DS vs. ARMS], p<0.0001 [D-HPLC/DS vs. L-
PCR]), and F317L (p=0.0148). In addition, differences
were significant for D-HPLC/DS vs. ARMS of V299L
(p=0.0072) and M351T (p=0.0267) and for D-HPLC/DS
vs. L-PCR of F359V (p=0.0117).
Comparison of amplification refractory mutation 
system- and ligation- polymerase chain reaction
The 187 mutations not found by DS and/or D-
HPLC/DS are here referred to as low-level mutations
(Figure 2B). Sixty-two of these 187 mutations (33%) were
independently detected by ARMS and L-PCR [G250E
(n=4), Q252H (n=1), Y253H (n=9), E255K (n=15), E255V
(n=1), V299L (n=3), T315I (n=12), F317L (n=9), M351T
(n=2), F359V (n=6)] with a median proportion of mutant
alleles of 1.7% (range 0.04-100%) BCR-ABLmutant/BCR-
ABLtotal. In addition 125 of the 187 mutations (67%) not
found by D-HPLC/DS were detected by one ASO PCR
technique only, with a lower median proportion of
mutant alleles of 0.73% (range 0.01-100%) BCR-
ABLmutant/BCR-ABLtotal. Of these 125 mutations, 48 (38%)
were detected by ARMS only: G250E (n=6), Q252H
(n=1), Y253H (n=7), E255K (n=4), V299L (n=5), T315I
(n=6), F317L (n=9), M351T (n=8), F359V (n=2). The other
77 (62%) were detected by L-PCR only: Q252H (n=1),
Y253H (n=7), E255K (n=4), E255V (n=2), V299L (n=1),
T315I (n=40), F317L (n=8), M351T (n=5), F359V (n=9).
Differences in the number of detected mutations
between ARMS and L-PCR were significant for the
T315I mutation only (p<0.0001, Fisher’s exact test).
Comparison of different BCR-ABL mutation detection methods in CML patients
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Table 2. Number of mutations at baseline and during 12 months of second-line TKI therapy detected by different mutation analysis methods.
Baseline (month 0) Dasatinib (months 3-6-9-12) Nilotinib (months 3-6-9-12)
D-HPLC/DS ARMS L-PCR D-HPLC/DS ARMS L-PCR D-HPLC/DS ARMS L-PCR
M244V 2 -- -- 0 -- -- 0 -- --
G250E 3 5 4 6 9 7 6 11 7
Q252H 1 1 1 0 1 2 0 1 0
Y253H 2 4 5 1 8 5 0 7 9
Y253F 1 1 1 0 0 0 4 4 4
E255K 1 3 4 0 9 8 6 14 14
E255V 1 2 4 4 4 4 4 4 4
D276G 1 -- -- 0 -- -- 1 -- --
T277A 0 -- -- 3 -- -- 0 -- --
V299L 0 0 0 0 5 4 0 3 0
F311L 1 -- -- 0 -- -- 2 -- --
F311I 0 -- -- 0 -- -- 3 -- --
T315I 2 2 4 9 18 35 4 13 28
F317L 1 6 7 13 18 18 0 6 5
L324Q 1 -- -- 3 -- -- 0 -- --
L341L 0 -- -- 0 -- -- 1 -- --
M351T 4 8 6 0 2 1 0 4 4
E355A 0 -- -- 0 -- -- 2 -- --
E355G 2 -- -- 0 -- -- 0 -- --
F359V 2 4 4 0 2 1 8 12 20
L387F 1 -- -- 2 -- -- 0 -- --
M388L 1 -- -- 2 -- -- 0 -- --
H396R 4 -- -- 0 -- -- 7 -- --
H396P 1 -- -- 4 -- -- 0 -- --
E453K 1 -- -- 0 -- -- 0 -- --
E459K 3 -- -- 1 -- -- 1 -- --
E466X 0 -- -- 0 -- -- 1 -- --
C475Y 0 -- -- 1 -- -- 1 -- --
F486S 1 -- -- 3 -- -- 2 -- --
--: not investigated by the respective method; D-HPLC/DS: D-HPLC in combination with direct sequencing; ARMS: amplification refractory mutation system PCR; L-PCR: liga-
tion-PCR.
Table 3. Comparison of the four different mutation analysis methods for 11 key mutations.
DS D-HPLC/DS ARMS L-PCR
Total number of detected mutations 79 83 191 220
Additionally detected mutations to DS − 4 112 142
Additionally detected mutations to D-HPLC/DS 0 − 110 139
Additionally detected mutations to ARMS 0 0 − 77
Additionally detected mutations to L-PCR 0 0 48 −
DS: direct sequencing; D-HPLC/DS: D-HPLC in combination with direct sequencing; ARMS: amplification refractory mutation system PCR; L-PCR: ligation-PCR.
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Evaluation of the diagnostic window for emerging
drug-resistant clones and follow-up of pre-existing
clones
We examined whether or not the greater sensitivity of
ASO PCR could be exploited for clinically relevant pur-
poses. Two categories of mutant clones were investigat-
ed: (i) clones harboring baseline mutations which disap-
peared according to D-HPLC/DS during second-line TKI
treatment (n=10); and (ii) clones emerging by D-
HPLC/DS upon second-line TKI treatment (n=15). ASO
PCR detection of these clones was compared to D-
HPLC/DS detection in serial samples (Figure 3). ARMS
allowed a median 6 months (range, 0-9 months) longer
follow-up of pre-existing clones than did D-HPLC/DS.
By L-PCR, pre-existing mutant clones were traceable for
a median of 3 months (range, 0-9 months) longer.
Regarding clones emerging during treatment, both ASO
PCR techniques detected mutant clones a median of 3
months (range, 0-12 months) earlier than did D-
HPLC/DS. Overall, pre-existing mutations were trace-
able for a median of 4.5 months longer and emerging
clones were detectable 3.0 months earlier by ASO PCR
than by D-HPLC/DS.
Association of detected mutations and clinical char-
acteristics
All mutational findings of DS, D-HPLC/DS, ARMS
and L-PCR at the four study time points (months 3, 6, 9,
and 12) were correlated with the clinical characteristics,
disease phase, second-line TKI treatment (dasatinib or
nilotinib), and a BCR-ABL/total ABL level ≤0.1% at 12
months. Only F317L findings showed associations with
clinical characteristics. One F317L mutation had been
identified by D-HPLC/DS at baseline but was only
detectable by ARMS and L-PCR at 3 months and
became undetectable thereafter during nilotinib therapy
by all techniques. In contrast, four patients on dasatinib
(chronic phase, n=1; accelerated phase, n=2; myeloid
blast crisis, n=1) but no patient on nilotinib showed a
F317L mutation after 12 months by D-HPLC/DS
(p=0.0392, Fisher’s exact test). Each of these mutations
was already detectable by at least one of the ASO PCR
techniques at a low level at baseline and became
detectable by D-HPLC/DS after 3 (n=2), 6 and 9 months,
respectively. However, more data are needed for a satis-
factory investigation of the influence of an interaction
between treatment and progression on the development
of a F317L mutation.
Figure 2. (A) Comparison of both ASO PCR methods for high-level
mutations (i.e. mutations which were also detected by D-
HPLC/DS). Eighty of 83 high-level mutations (96%) were inde-
pendently detected by both ASO methods. Hatched areas corre-
spond to mutations which were detected by both ASO methods in
the same sample. ARMS detected one G250E mutation which
was not detected by L-PCR and L-PCR revealed one F317L muta-
tion which was not detected by ARMS. (B) Comparison of both
ASO PCR methods for low-level mutations (i.e. mutations which
were not detected by D-HPLC/DS). Sixty-two of 187 low-level
mutations (33%) were independently detected by both ASO tech-
niques (hatched areas). Forty-eight low-level mutations were
detected by ARMS only and 77 by L-PCR only. L-PCR detected sta-
tistically significantly more T315I low-level mutations than did
ARMS (p<0.0001).
Figure 1. Comparison of the number of mutations detected by the
four different mutation analysis methods (for a panel of 11 key
mutations). In total, 200 blinded cDNA samples prior to and dur-
ing second-line TKI therapy were simultaneously analyzed by all
techniques. Differences between direct sequencing and D-
HPLC/DS were not statistically significant. For Y253H, E255K,
T315I, and F317L, statistically significant differences were
observed between D-HPLC/DS and both ASO methods. Numbers
over the bars indicate p values in cases of statistically significant























































































































































































Since the introduction of imatinib and the discovery
of BCR-ABL kinase domain mutations as the main
mechanism of resistance, mutation detection in the case
of treatment failure or suboptimal response has become
an increasingly important issue in the management of
CML patients.24 With the availability of second-genera-
tion TKI with different in vitro4,5 and in vivo30,31 activity
against mutant clones, the presence of mutations pro-
vides information relevant to the selection of the opti-
mal second- or third-line treatment. However, a range
of different screening and mutation detection tech-
niques has been employed. Here, we present a blinded
comparison of D-HPLC screening followed by DS and
DS alone initiated by investigators of the European
LeukemiaNet. Consistent with the higher sensitivities
expected from the smaller PCR fragments amplified in
D-HPLC/DS, we detected 13 additional mutations
(+11.4%) by this technique. However, only four of
these samples were diagnosed as wild-type by DS
alone. Thus, in our study the higher sensitivity of D-
HPLC/DS resulted mainly in the detection of second or
third mutated clones (n=9). However, D-HPLC/DS has
some additional advantages: first, the initial screening
for mutations by D-HPLC has proven to be more rapid
and cost-effective in our hands than the full procedure
of DS. Second, the three overlapping fragments effec-
tively cover the entire BCR-ABL kinase domain (amino
acids 207-517) compared with the two fragments
(amino acids 207-414) analyzed by DS. Taken together,
in our study both techniques were suitable and closely
comparable for the detection of major resistant clones in
cases of resistance or suboptimal response to TKI treat-
ment in CML. Since there are other techniques available
with different laboratory-specific modifications and
applications, this study provides a basis for further com-
parisons and standardization efforts comparable with
the introduction of the international scale for quantifica-
tion of BCR-ABL transcripts.32
Another aim of our study was to perform a blinded
comparison of D-HPLC/DS vs. two ASO PCR tech-
niques which are currently experimental but potentially
more sensitive and quantitative. So far, these techniques
have been employed not for mutation screening, but
rather to follow known mutated clones over time
(ARMS)21 or to provide accurate quantification of specif-
ic mutant clones (L-PCR).23 Taking the mutations detect-
ed by D-HPLC/DS as a high level reference, both ASO
PCR techniques showed a low false negative rate, miss-
ing only two of 83 mutations (2.4%). Among the muta-
tions detected by both ASO PCR and D-HPLC/DS, the
lowest proportion quantified by ASO PCR was 0.79%
BCR-ABLmutant/BCR-ABLtotal, confirming the reported sen-
sitivity of the D-HPLC/DS technique. The higher sensi-
tivities of the ASO PCR techniques resulted in the
detection of 187 additional mutations referred to here as
low level mutations. The difference in the incidence of
detected mutations compared to D-HPLC/DS was sig-
nificant for six (ARMS) and five (L-PCR) of eleven muta-
tions tested. Among low-level mutations identified by
ASO PCR, 33% were confirmed independently by both
techniques. These clones were present at a higher level
(median 1.7% BCR-ABLmutant/BCR-ABLtotal) than the
unconfirmed mutations (median 0.73% BCR-
ABLmutant/BCR-ABLtotal), suggesting that the discrepancies
between the results of the two ASO PCR techniques
usually occur below a level of 1% mutant clones. Only
ASO PCR results with Ct values below the cross-reac-
tivity of every specific run were scored as positive, so
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Figure 3. Evaluation of the diagnostic
window for emerging drug-resistant
clones and follow-up of pre-existing
clones as obtained by ASO PCR versus
D-HPLC/DS. A total of 15 mutant
clones emerged and 10 pre-existing
clones disappeared as detected by D-
HPLC/DS over a 12-month period of
second-line TKI treatment. Detection
of these clones by ASO PCR was com-
pared to that by D-HPLC/DS in serial
samples. For individual mutations the
respective median differences
(months) compared to D-HPLC/DS are
illustrated by bars. ASO PCR detected
emerging mutations a median of 3.0
months earlier and traced pre-existing
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we can largely exclude false positive results for both
ASO PCR techniques.
Given that the implications for high sensitivity and
quantitative mutation testing in the specific manage-
ment of CML patients are unknown, we considered: (i)
whether we could identify associations with clinical
characteristics, and (ii) whether we were able to increase
the diagnostic window for detection of emerging or pre-
existing clones prior to progression. 
Due to the fact that this study was set up with the pri-
mary aim of comparing different techniques, only a lim-
ited number of patients and clinical characteristics were
available. However, we observed more emerging F317L
mutant clones on dasatinib therapy (n=4) than on nilo-
tinib therapy (n=0) within 12 months. All of these F317L
clones were already detectable at a very low level by the
ASO PCR techniques prior to initiation of dasatinib.
Furthermore, we observed an association of F317L muta-
tions and advanced disease phase, as previously report-
ed.33 The low number of patients with F317L did not
enable a test for independency of these two characteris-
tics. Therefore, more data are needed to investigate the
interaction between advanced disease phase, dasatinib
treatment and the occurrence of a F317L mutation as well
as the additional role of high sensitivity mutation testing.
As reported for the specific D-HPLC/DS technique
used in this study, BCR-ABL mutations were detectable
a median of 7.1 months prior to hematologic relapse.13
The ASO PCR techniques might further increase the
diagnostic window from 7.1 to 10.1 months, by detect-
ing the G250E, E255K/V, T315I, F317L and F359V muta-
tios 3 months earlier than D-HPLC/DS can do. Almost
all of these mutations have been shown to arise on treat-
ment or have lower response rates to dasatinib (IC50>3
nM; Q252H, E255K/V, V299L, F317L, T315I), or nilo-
tinib (IC50>150 nM; Y253H, E255K/V, F359V/C,
T315I).30,31 Hence, 3-monthly serial monitoring by D-
HPLC/DS for patients on second-line TKI treatment and
an unsatisfactory response is likely to be useful. A fur-
ther increase of the diagnostic window by using more
sensitive techniques provides an opportunity for earlier
optimization of the TKI therapy and increases the time
available for identification of a stem cell donor in those
cases in which allogeneic transplantation is an option.
Based on the current study, this goal should be achiev-
able by serial monitoring of those mutations at risk on
the specific treatment (i.e. IC50>3 nM for dasatinib and
IC50>150 nM for nilotinib). It remains to be seen whether
threshold levels of mutant clones or the kinetics of
increase over time would be most informative in this
respect. Based on this study and considering the narrow-
ing spectrum of mutations causing resistance on second-
or third-line TKI treatment, we foresee potential advan-
tages for highly sensitive and quantitative monitoring of
mutant clones in the future management of CML
patients with an unsatisfactory response. 
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